Table 3.
Baseline |
12-month follow-up |
|||||
---|---|---|---|---|---|---|
n | Brain volume, mL | BSI | n | Brain volume*, mL | BSI† | |
1·5 T | ||||||
Losartan group | 22 | 1021 (100) | .. | 15 | 987 (84) | 20·9 (10·8) |
Placebo group | 22 | 1051 (103) | .. | 17 | 1033 (109) | 21·9 (11·6) |
3 T | ||||||
Losartan group | 83 | 1023 (100) | .. | 69 | 1005 (102) | 19·8 (10·8) |
Placebo group | 84 | 1032 (114) | .. | 70 | 1015 (114) | 18·4 (9·9) |
Data are n or mean (SD). Repeat of main primary analysis including treatment group by scan modality (1·5 T vs 3 T) interaction term. BSI=boundary shift interval.
p=0·93.
p=0·73